Clinical Trial Search

Primary: Count Of Participants With Treatment-Emergent Adverse Events — 55; 59; 3; 5 Participants

Primary: RAD001 Response Rate Based on 2D MRI Change From Baseline — 15 participants — p=<0.001

Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190

Primary: Mean Change of Tissue Factor Bearing Microparticles — 102; -618 microparticles per microliter

Primary: Difference in Mean Patient Health Questionaire 9 Score From Baseline — .74; 3.38 units on a scale — p=<.009

Primary: Leg Muscle Strength With and Without tDCS. — 323; 330 Newtons

Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours

Primary: SVR After G/P 12 Wks (Arm A) vs. G/P Given for 16 Weeks (Arm B) to Non-cirrhotic Treatment-experienced GT1 HCV Participants — 70; 46; 8; 3 Participants

Primary: One-repetition Maximum of Wrist Extensors — 22.6; 23.7; 32.0; 29.9 lbs — p=0.002

Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001

Primary: Percent Change in Radiation Dose to Healthy Human Tissue. — 3.0; 31.0; 25.0; 2.0 Percent change in radiation dose

Primary: 50 Percent (%) Responder Rate for Partial Onset Seizure With or Without Secondary Generalization — 80.0 percentage of participants

Primary: Child Behavior Measured by Strengths and Difficulties Questionnaire (Goodman, 1997) — 19.27; 21.00 total score on a scale — p=.598

Primary: Attendance Rates at Respiratory Outpatient Clinics — 183; 89 Participants — p=0.004

Primary: Percentage of Participants With an Adverse Event (AE) — 89.9; 84.4 Percentage of participants